Using stem cell messengers to protect vision after retinal damage
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage
This project explores a new cell-free approach using tiny messengers from stem cells to protect vision in people experiencing sudden vision loss from a blocked retinal artery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11110337 on NIH RePORTER |
What this research studies
Central retinal artery occlusion (CRAO) is a serious eye emergency that can cause sudden vision loss, and current treatments are limited. While stem cell therapies show promise for protecting the retina, they have challenges like immune reactions. This work focuses on using tiny packages called extracellular vesicles (EVs) from stem cells, which are like messengers carrying beneficial molecules. We are specifically engineering these EVs to deliver protective microRNAs that can help rescue retinal cells from damage and inflammation. This cell-free method aims to be safer and more targeted than traditional stem cell approaches.
Who could benefit from this research
Good fit: This research is foundational for patients who experience sudden vision loss due to a blocked artery in the eye, known as central retinal artery occlusion (CRAO).
Not a fit: Patients with vision loss from causes other than acute ischemic retinal damage may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could offer a new and effective way to protect vision and prevent permanent damage for patients experiencing central retinal artery occlusion.
How similar studies have performed: While stem cell therapies for retinal diseases are being explored, this specific cell-free approach using engineered extracellular vesicles with targeted microRNAs is a novel strategy.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Roth, Steven — University of Illinois at Chicago
- Study coordinator: Roth, Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.